July 22, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Adults with ADHD and comorbid anxiety experienced improvements in both with centanafadine, according to a press release from Otsuka Pharmaceutical. Currently under investigation, centanafadine is a norepinephrine, dopamine and serotonin reuptake inhibitor that Otuska called first-in-class.
July 22, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

Otsuka Receives FDA Approval for First-in-Class SIMTRIYO® (centanafadine) for the Treatment of Attention-Deficit Hyperactivity…

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the…

Twenty to 30 per cent of people with ADHD also live with anxiety. Experts share their advice for recognising and managing the two…

About 2.6 million people in the UK live with attention deficit hyperactivity disorder (ADHD) , but in the just over half are…

ORLANDO — Among adults with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo…